Immunovant Statistics
Total Valuation
Immunovant has a market cap or net worth of $2.50 billion. The enterprise value is $2.13 billion.
Important Dates
The next estimated earnings date is Wednesday, May 28, 2025, after market close.
| Earnings Date | May 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunovant has 169.86 million shares outstanding. The number of shares has increased by 9.00% in one year.
| Current Share Class | 169.86M |
| Shares Outstanding | 169.86M |
| Shares Change (YoY) | +9.00% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 0.89% |
| Owned by Institutions (%) | 46.26% |
| Float | 62.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.15 |
| P/TBV Ratio | 7.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.04, with a Debt / Equity ratio of 0.00.
| Current Ratio | 6.04 |
| Quick Ratio | 5.52 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -74.17% and return on invested capital (ROIC) is -49.07%.
| Return on Equity (ROE) | -74.17% |
| Return on Assets (ROA) | -44.73% |
| Return on Invested Capital (ROIC) | -49.07% |
| Return on Capital Employed (ROCE) | -114.91% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.85M |
| Employee Count | 207 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Immunovant has paid $540,000 in taxes.
| Income Tax | 540,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.03% in the last 52 weeks. The beta is 0.81, so Immunovant's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -49.03% |
| 50-Day Moving Average | 17.85 |
| 200-Day Moving Average | 25.31 |
| Relative Strength Index (RSI) | 41.22 |
| Average Volume (20 Days) | 2,191,207 |
Short Selling Information
The latest short interest is 20.83 million, so 12.26% of the outstanding shares have been sold short.
| Short Interest | 20.83M |
| Short Previous Month | 19.69M |
| Short % of Shares Out | 12.26% |
| Short % of Float | 33.49% |
| Short Ratio (days to cover) | 7.81 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -405.21M |
| Pretax Income | -271.89M |
| Net Income | -382.71M |
| EBITDA | -404.87M |
| EBIT | -405.21M |
| Earnings Per Share (EPS) | -$2.62 |
Full Income StatementBalance Sheet
The company has $374.69 million in cash and $23,000 in debt, giving a net cash position of $374.66 million or $2.21 per share.
| Cash & Cash Equivalents | 374.69M |
| Total Debt | 23,000 |
| Net Cash | 374.66M |
| Net Cash Per Share | $2.21 |
| Equity (Book Value) | 352.62M |
| Book Value Per Share | 2.40 |
| Working Capital | 344.23M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$324.94 million and capital expenditures -$708,000, giving a free cash flow of -$325.64 million.
| Operating Cash Flow | -324.94M |
| Capital Expenditures | -708,000 |
| Free Cash Flow | -325.64M |
| FCF Per Share | -$1.92 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |